Docket No.

281760US0PCT

IAP20 RES'17 11 15 DEC 2005

IN	THE	UNITED	STATES	PATENT	AND	TRADEMARK	OFFICE
----	-----	--------	--------	--------	-----	-----------	--------

IN RE APPLICATION OF: Angelo C

Angelo GUGLIELMOTTI, et al.

SERIAL NO: New U.S. PCT Application Based on PCT/EP04/07633

GAU:

FILED:

Trem 0.5. For Application Based on Forth officer

0..0.

FOR:

Herewith EXAMINER:

PAIN

USE OF 2H-[1,3]-OXAZINO [3, 2-A] INDOLE DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

Form PTO 1449	U.S. DEPARTMENT OF COMMERCE		OF COMMERCE	ATTY DOCKET NO.		SERIAL NO			
(Modified) PATENT AND TRADEMARK OFFICE			281760US0PCT	New/U.S. (PC) Application Based on PCT/EP04/07633					
				APPLICANT					
LIST OF	REFE	RENCES CITED BY APP	PLICANT	Angelo GUGLIELMOTTI, et al.					
				FILING DATE		GROUP			
				Herewith					
				U.S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE				ILING DATE PPROPRIATE		
AA 5 817 676 10/06/98 CATLOW			CATLOW et al.						
			FO	REIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY		YES		LATION NO	
	AB	0 630 376	12/28/94	EP				NO	
	AC	0 884 319	12/16/98	EP				NO	
	AD	93/06108	04/01/93	wo				NO	
·	'			Including Author, Title, Date, Pertinent					
	AE	HOUGHTON et al. "5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit", Aliment Pharmacol Ther, vol. 13, pages 1437-1444							
	AE	1999 DOAK et al. "Formalin-Induced Nociceptive Behavior and Edema: Involvement of Multiple Peripheral 5-Hydroxytryptamine Receptor Subtypes", Neuroscience, vol. 80, pages 939-949 1997							
	AG	DONAHUE et al. "Electrolytic lesion of the anterior cingulate cortex decreases inflammatory, but not neuropathic nociceptive behavior in rats", Brain Research, vol. 897, pages 131-138							
	AH	BEERS et al. "The Merck Manual of Diagnosis and Therapy", Merck Research Laboratories, page 1371-1372, 17 th edition 1999							
	AI	WEI et al. "Influence of Two Serotonin Receptor Antagonists in Neuropathic Rats", Pfluegers Archiv European Journal of Physiology, vol. 443, no. supplement 1, page S181 2002							
	AJ	ASHBURN et al. "Management of chronic pain", The Lancet, vol. 353, 1865-1869 1999							
	AK	WOOLF et al. "Neuropathic pain: aetiology, symptoms, mechanisms, and management", The Lancet, vol. 353, pages 1959- AK 1964 1999							
	SCHOLZ et al. "Can we conquer pain?", Nature Neuroscience Supplement, vol. 5, pages 1062-1067 AL 2002								
	SELTZER et al. "A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury", AM Pain, vol. 43, pages 205-218 1990								
	AN	BENNETT et al. "A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man", Pain, vol. 33, pages 87-107							
	AO	1988 COURTEIX et al. "Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain", Pain, vol. 53, pages 81-88 1993							
	AP	BANNON et al. "ABT-594, a novel cholinergic channel modulator, is							
Examiner				Date Cor	ate Considered				
*Examiner: In conformance	itial if r	eference is considered, of considered. Include co	whether or no	t citation is in conformance with MPEP 60 with next communication to applicant.	9; Draw li	ne through	citation	if not in	

New U.S. PCT Application Based on PCT/EP04/07633 Docket No.: <u>281760US0PCT</u>

STATEMENT OF RELEVANCY

			have been cited in the International S	
Cc	pies of these r	eferences are	being submitted herewith only when no	ot automatically
pre	ovided by the I	nternational	Searching Authority.	
			ve been cited in the correspondingbeing submitted herewith.	Search Report.
	References _ ferences is beir		are discussed in the specification. A cohere with.	opy of these
•	· · · · · · · · · · · · · · · · · · ·		e additional prior art known to Applicar	nt. A copy of